NCT02707809

Brief Summary

The microcirculation is altered in acute kidney injury and chronic kidney disease. The microcirculation is poor in end-stage renal disease patients receiving hemodialysis. Kidney transplant can improve the life quality of these patients. However, surgical stress and inflammatory response may cause microcirculatory dysfunction and intestinal injury. Moreover, the transplanted kidney would suffer from the ischemia and reperfusion injury, and it may result in acute kidney injury. In ischemia and reperfusion injury animal model, dexmedetomidine has been proven to attenuate kidney and intestinal injury. In our previous study of surgical stress and pain stimulation rat model, we found that dexmedetomidine attenuate the intestinal microcirculatory dysfunction. In patients receiving coronary artery bypass graft surgery, dexmedetomidine increases urine output and decreases postoperative serum level of neutrophil gelatinase-associated lipocalin. This study aims to investigate whether perioperative dexmedetomidine infusion may attenuate microcirculatory dysfunction, kidney injury, and intestinal injury for patients undergoing kidney transplant.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Aug 2016

Typical duration for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 9, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

March 14, 2016

Completed
5 months until next milestone

Study Start

First participant enrolled

August 1, 2016

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2019

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2019

Completed
Last Updated

December 17, 2020

Status Verified

April 1, 2020

Enrollment Period

2.7 years

First QC Date

March 9, 2016

Last Update Submit

December 13, 2020

Conditions

Outcome Measures

Primary Outcomes (2)

  • Total small vessel density of sublingual microcirculation

    Sublingual microcirculation captured using an incident dark-field video microscope

    Postoperative 2h

  • Creatinine level

    Difference in serum creatine levels between the two groups

    Postoperative day 2

Study Arms (2)

Control

NO INTERVENTION

Routine anesthesia care for kidney transplant

Dexmedetomidine

EXPERIMENTAL

Routine anesthesia care for kidney transplant and perioperative intravenous infusion of dexmedetomidine

Drug: Dexmedetomidine

Interventions

Dexmedetomidine infusion

Also known as: Precedex
Dexmedetomidine

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • kidney transplant recipient

You may not qualify if:

  • allergic history to dexmedetomidine
  • refractory bradycardia \< 60 bpm despite treatment
  • severe atrioventricular block (2nd and 3rd degree)
  • previous operation of tongue

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Taiwan University Hospital

Taipei, 100, Taiwan

Location

MeSH Terms

Conditions

Kidney Diseases

Interventions

Dexmedetomidine

Condition Hierarchy (Ancestors)

Urologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Yu-Chang Yeh, PhD

    National Taiwan University Hospital

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 9, 2016

First Posted

March 14, 2016

Study Start

August 1, 2016

Primary Completion

May 1, 2019

Study Completion

July 1, 2019

Last Updated

December 17, 2020

Record last verified: 2020-04

Data Sharing

IPD Sharing
Will not share

Locations